Skip to content
Company Analysis

Biodesix, Inc. BDSX

A comprehensive view of key metrics, scores, and financial health for Biodesix, Inc.

Overview of Biodesix, Inc.

BDSX NGM
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Micro Cap
Biodesix, Inc. (BDSX), is a Micro Cap company, in the Diagnostics & Research industry, last closed at $21.26, about 62.0% overvalued vs fair value, +224.6% 1Y return, ranked 493/1145 in sector.
Metrics Rev Growth 24.1% ROE -383.1% Gross Margin 81.1%
USD 21.26
0.38%
(Delayed)
• Vol 90d: 81.5%
52-Week Range
Market Cap
$224.32M
Enterprise Value
$241.14M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 88%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.biodesix.com
HQ Louisville, CO
Employees 273
Fiscal year Dec 31

Next Events

Earnings Nov 5 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$7
$8
$10
Current: $21.26 -62% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$88.5M
24.1%%
Gross Profit
$71.8M
28.8%%
Operating Income (GAAP)
-$27.9M
19.2%%
EBITDA
-$21.9M
24.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
81.1%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Biodesix, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
51
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.98). This signals strong consumable attach-rate economics.
  • Improving FCF Trend FCF trend score is positive (score 0.85). Improving FCF margin signals compounding operational leverage.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.20). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.29). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
70
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 79% Coverage
Trade-Off Triangle Visualization A ternary plot showing BDSX's balance between Growth (46.5%), Profitability (33.7%), and Safety (19.8%). Growth 47% Safety 20% Profitability 34%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

67th percentile vs peers
68
Key Signals
Rev Growth YoY 24.1% 81p Revenue CAGR 3Y 32.3% 85p EPS Growth YoY 29.5% 55p TSR -19.7% 36p Asset Growth YoY -10.0% 25p
Strengths
  • Rev Growth YoY in top 20% of peers (24.1%, 81th percentile)
  • Revenue CAGR 3Y in top 20% of peers (32.3%, 85th percentile)
  • Gross Profit Margin in top 20% of peers (81.1%, 89th percentile)
  • Growth above peer median with strong metric coverage (85%)
Risks

No significant risks identified for this axis.

Profitability

49th percentile vs peers
49
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

28th percentile vs peers
29
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Biodesix, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$8.07
- - -
-62.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000